[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
3. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, Eary JF: Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer; 2005 Jan 15;103(2):339-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
  • BACKGROUND: Patients with high-grade soft tissue sarcomas are at high risk of developing local disease recurrence and metastatic disease.
  • [F-18]-fluorodeoxy-D-glucose (FDG) positron emission tomography (PET) scans are hypothesized to detect histopathologic response to therapy and to predict risk of tumor progression in patients with various malignancies.
  • Serial FDG-PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas.
  • The maximum standardized uptake values (SUVmax) of tumors were measured before receipt of neoadjuvant chemotherapy and again before surgery.
  • Patients were followed up at least annually for evidence of local and distant recurrence of disease and survival.
  • RESULTS: Patients with a baseline tumor SUVmax >/= 6 and < 40% decrease in FDG uptake were at high risk of systemic disease recurrence estimated to be 90% at 4 years from the time of initial diagnosis.
  • Patients whose tumors had a >/= 40% decline in the SUVmax in response to chemotherapy were at a significantly lower risk of recurrent disease and death after complete resection and adjuvant radiotherapy.
  • CONCLUSIONS: The FDG-PET scan was found to be a useful method with which to predict the outcomes of patients with high-grade extremity soft tissue sarcomas treated with chemotherapy.
  • The pretreatment tumor SUVmax and change in SUVmax after neoadjuvant chemotherapy independently identified patients at high risk of tumor recurrence.
  • The FDG-PET scan showed promise as a tool to identify the patients with sarcoma who are most likely to benefit from chemotherapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography. Sarcoma / drug therapy. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Staging. Orthopedic Procedures / methods. Probability. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome. Upper Extremity

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15578712.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA65537; United States / NCI NIH HHS / CA / CA76930; United States / NCI NIH HHS / CA / CA87721
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Kroon HM, Lin DY, Kam PC, Thompson JF: Major amputation for irresectable extremity melanoma after failure of isolated limb infusion. Ann Surg Oncol; 2009 Jun;16(6):1543-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major amputation for irresectable extremity melanoma after failure of isolated limb infusion.
  • INTRODUCTION: Isolated limb infusion (ILI) is an effective, minimally invasive treatment option that delivers high-dose regional chemotherapy to treat metastatic melanoma confined to a limb.
  • In some patients, however, locoregional disease does not respond to the treatment or extensive recurrence occurs so that an amputation may become inevitable.
  • RESULTS: Following ILI, three patients had a complete response, seven had a partial response, two had stable disease and two patients had progressive disease.
  • Amputation was performed in six of 20 patients who had been treated with an upper limb ILI, compared to eight amputations that were performed in 215 patients who had been treated with a lower limb ILI (P = .001).
  • Five patients developed stump recurrence after amputation; these were treated by excision or radiation.
  • CONCLUSIONS: Amputation following upper extremity ILI is more common compared to lower extremity ILI.
  • Amputation may provide effective long-term palliation in selected patients when there is extensive inoperable progressive or recurrent disease after ILI.
  • [MeSH-major] Amputation. Chemotherapy, Cancer, Regional Perfusion. Melanoma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Lower Extremity / surgery. Male. Middle Aged. Treatment Failure. Treatment Outcome. Upper Extremity / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352777.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Fraker DL: Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol; 2004 Jun;5(3):173-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of in-transit melanoma of the extremity with isolated limb perfusion.
  • In-transit metastases for melanoma are a type of stage III regional metastatic disease that are intradermal or subcutaneous nodules growing within lymphatics and not in nodal basins.
  • There is no role for wide excision of in-transit lesions as there is for primary melanoma because the entire extremity or that region of the body is at risk for recurrence.
  • Patients who are diagnosed with additional lesions in a short period of time or patients who at initial diagnosis have large numbers of nodules are candidates for isolated limb perfusion (ILP).
  • ILP is a regional administration of high-dose chemotherapeutics within an extremity using a cardiopulmonary bypass machine similar to cardiac surgery.
  • Once isolation is obtained surgically, the limb is heated to what is considered mild hyperthermia (38.5 degrees -40 degrees C), then chemotherapeutics are administered at very high concentrations for a 60- to 90-minute treatment.
  • The drug recirculates and, at the end of the treatment period, it is flushed from the extremity and the circulation is re-established.
  • The optimal regimen is melphalan dosed per limb volume (10 mg/L limb volume for lower extremities and 13 mg/L limb volume for upper extremities) with mild hyperthermia for 60 minutes.
  • There have been several studies adding high-dose tumor necrosis factor to ILP, but there is no clear benefit in the treatment of melanoma.
  • Other new approaches include isolated limb infusion as a percutaneous procedure to avoid the surgical toxicity.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Extremities. Humans. Hyperthermia, Induced. Neoplasm Metastasis. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):566-72 [11508617.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):479-89 [8636761.001]
  • [Cites] Surgery. 1994 Jan;115(1):39-45 [8284759.001]
  • [Cites] Melanoma Res. 1999 Oct;9(5):491-502 [10596916.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):654-9 [3276384.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):483-92 [8293417.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):382-8 [7850539.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Curr Probl Surg. 1999 Nov;36(11):841-907 [10569114.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(1):35-42 [9923539.001]
  • [Cites] Cancer J Sci Am. 1995 Nov-Dec;1(4):274-80 [9166488.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):264-73 [7799030.001]
  • [Cites] Melanoma Res. 2001 Aug;11(4):423-31 [11479432.001]
  • [Cites] World J Surg. 1992 Mar-Apr;16(2):227-33 [1561803.001]
  • [Cites] Eur J Surg Oncol. 1999 Oct;25(5):503-8 [10529261.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2091-4 [1960549.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(6):517-22 [11138466.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):52-60 [1727926.001]
  • [Cites] J Am Coll Surg. 1994 Jun;178(6):564-72 [8193749.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2906-12 [9738557.001]
  • [Cites] Surg Gynecol Obstet. 1975 Mar;140(3):339-48 [1114425.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1224-9 [8393368.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):639-43 [3791248.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10 [6891640.001]
  • [Cites] Surg Gynecol Obstet. 1989 Jul;169(1):1-6 [2472674.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):1009-16 [7646901.001]
  • [Cites] Ann Surg Oncol. 2000 May;7(4):268-75 [10819366.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):522-30 [10235581.001]
  • [Cites] World J Surg. 1992 Mar-Apr;16(2):234-40 [1561804.001]
  • [Cites] Ann Surg. 1994 Oct;220(4):520-34; discussion 534-5 [7944662.001]
  • (PMID = 15115646.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


6. Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, Picci P, Mercuri M, Bacci G, Ferrari S: Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer; 2009 Jul 1;115(13):2988-98
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The optimal treatment for synovial sarcoma remains controversial.
  • Treatment, outcome, and prognostic factors in patients treated in a single institution were examined.
  • RESULTS: Characteristics of the 250 patients (128 female; 122 male) included: median age, 37 years (range, 7-83 years); 177 (71%) with tumors in the lower extremity, 40 (16%) with tumors in the upper extremity, and 33 with tumors in the trunk (13%); primary lesion size >5 cm in 121 patients (55%); and 204 (82%) patients with localized disease and 46 (18%) with metastatic disease at the time of presentation.
  • All patients with localized disease underwent surgery.
  • In patients with localized disease, radiotherapy was administered to 103 (50%) patients, and chemotherapy to 98 (48%).
  • With a median follow-up of 5.5 years (range, 1-30 years), the 5-year overall survival rate was 10% for patients with metastatic disease and 76% for patients with localized disease (P = .0001).
  • The 5-year event-free survival was 58% in patients with localized disease.
  • CONCLUSIONS: In those patients with localized disease, a good rate of cure can be achieved.
  • Age, size, histology, and use of radiotherapy influence prognosis, whereas to the authors' knowledge, the role of adjuvant chemotherapy remains unproven.
  • [MeSH-major] Sarcoma, Synovial / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arm. Disease-Free Survival. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452538.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N: Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res; 2009 Nov;467(11):2932-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
  • We examined expression levels of COX-2 immunohistochemically in 51 patients with extremity osteosarcoma who completed standard therapy and obtained complete initial regression of the tumor.
  • We found no correlation between COX-2 staining intensity and variables such as gender, age, anatomic site, necrosis after chemotherapy, and surgical stage.
  • Among seven patients with resectable lung metastasis, all three with greater COX-2 expression in the metastatic lesion than that in a primary site died of the disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / mortality. Bone Neoplasms / therapy. Cyclooxygenase 2 / blood. Osteosarcoma / mortality. Osteosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Risk Assessment. Survival Analysis. Treatment Outcome. Upper Extremity. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Orthop Res. 1999 Sep;17(5):629-32 [10569469.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jul;30(7):507-12 [18797196.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4064-8 [11051257.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):861-7 [11309334.001]
  • [Cites] Cancer. 2001 May 15;91(10):1876-81 [11346869.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4375-81 [11389063.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jul;84(5):706-11 [12188489.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):727-35 [12618527.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):282-5 [12679640.001]
  • [Cites] J Clin Immunol. 1983 Oct;3(4):295-315 [6140268.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):471-4 [9835898.001]
  • [Cites] Eur Respir J. 1999 Aug;14(2):412-8 [10515422.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):33-42 [16327977.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1154-61 [16421923.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):584-92 [16219634.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):70-6 [17536311.001]
  • [Cites] Exp Mol Med. 2007 Aug 31;39(4):469-76 [17934334.001]
  • [Cites] Prostate. 2000 Jan;42(1):73-8 [10579801.001]
  • (PMID = 19326179.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2758970
  •  go-up   go-down


8. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • In patients with extremity STS or bulky melanoma in-transit metastases, the local tumor burden may be so problematic that, even in patients with systemically metastasized disease, an amputation may be inevitable.
  • Isolated limb perfusion (ILP) has proven to be an excellent, local, limb-saving treatment option in patients with locally advanced extremity tumors.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • All patients underwent an ILP with TNF and melphalan of the upper limb (n = 4 patients) or the lower limb (n = 47 patients) with 26-140 mg melphalan and 2-4 mg TNF.
  • Limb salvage was achieved in 36 of 37 patients, with 1 patient undergoing amputation due to treatment toxicity.
  • CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


9. McMulkin HM, Yanchar NL, Fernandez CV, Giacomantonio C: Sentinel lymph node mapping and biopsy: a potentially valuable tool in the management of childhood extremity rhabdomyosarcoma. Pediatr Surg Int; 2003 Aug;19(6):453-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping and biopsy: a potentially valuable tool in the management of childhood extremity rhabdomyosarcoma.
  • Multimodal therapy, involving surgery, chemotherapy and radiation, now dominates the management of rhabdomyosarcoma (RMS) in childhood.
  • Yet, despite improvements in these practices, extremity tumors continue to fare relatively poorly.
  • Several investigators have identified prognostic factors that can be used to direct therapy and predict outcome.
  • These factors include histology and metastatic disease, the latter requiring accurate staging to identify.
  • The presence of lymph node metastases has been shown to be of prognostic significance and is incorporated into pre-treatment staging schemes.
  • Up to 50% of all surgically evaluated nodes and 17% of clinically negative nodes in extremity RMS may harbor tumor, underscoring the increased risk of understaging the disease if accurate lymph node dissection is not undertaken.
  • Despite its importance, there appears to be no standard format by which regional nodal status is evaluated in extremity RMS.
  • We describe a case in which sentinel node mapping and dissection were used to easily and accurately stage a distal upper extremity alveolar RMS in a child with clinically and radiologically negative regional lymph nodes.
  • The procedure yielded no positive nodes, was associated with no morbidity and spared the child more extensive radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2253-60 [9626228.001]
  • [Cites] Arch Surg. 1999 Jul;134(7):764-7 [10401830.001]
  • [Cites] Recent Results Cancer Res. 2000;157:141-9 [10857168.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):250-8 [11176132.001]
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):965-6 [10873045.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):428-32 [11037854.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):466-71 [2233517.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):961-4 [10873044.001]
  • [Cites] J Am Coll Surg. 1999 Aug;189(2):183-94 [10437841.001]
  • [Cites] Semin Oncol. 2001 Jun;28(3):229-35 [11402432.001]
  • [Cites] J Surg Oncol. 2001 Jul;77(3):157-64 [11455551.001]
  • [Cites] Surg Oncol. 1993 Dec;2(6):335-9; discussion 340 [8130940.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):2054 [11441859.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):608-14 [10649254.001]
  • [Cites] J Pediatr Surg. 1996 Jan;31(1):191-6 [8632278.001]
  • [Cites] Med Pediatr Oncol. 1991;19(2):89-95 [2011101.001]
  • [Cites] J Pediatr Surg. 1990 Feb;25(2):238-43; discussion 243-4 [2303993.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • (PMID = 12740706.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Rashid M, Hafeez S, Zia ul Islam M, Rizvi ST, ur Rehman S, Tamimy MS, Aman S: Limb salvage in malignant tumours of the upper limb using vascularised fibula. J Plast Reconstr Aesthet Surg; 2008 Jun;61(6):648-61
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage in malignant tumours of the upper limb using vascularised fibula.
  • After neoadjuvant chemotherapy, MRI was repeated and resectability assessed.
  • The average length of defect reconstructed was 18 cm and the average time for bone union was 7 months.
  • At a minimum follow up of 12 months, 21 patients were alive and disease free.
  • One patient required amputation due to recurrence and one died of metastatic disease.
  • CONCLUSION: Limb salvage in the upper limb using vascularised fibula in patients with malignant musculoskeletal tumours can result in good tumour control along with reasonable limb function.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Limb Salvage / methods. Upper Extremity / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Fibula / transplantation. Follow-Up Studies. Humans. Male. Middle Aged. Muscle, Skeletal / transplantation. Osteosarcoma / surgery. Recovery of Function. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158279.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Gow KW, Murphy JJ 3rd, Wu JK, Desa DJ: Metastatic testicular rhabdomyosarcoma--a report of two cases. J Pediatr Surg; 2003 Aug;38(8):E1-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic testicular rhabdomyosarcoma--a report of two cases.
  • Rhabdomyosarcoma is the most common type of soft tissue sarcoma in children.
  • Metastatic spread to the testicle has been rarely described.
  • The first patient, an 11-year-old boy presented with primary disease in his left foot and an enlarged testicle.
  • A second boy 17 years of age had a primary tumor involving the left upper extremity treated with amputation, chemotherapy, and radiotherapy.
  • The authors discuss the implications and the management of this rare presentation of metastatic rhabdomyosarcoma.
  • [MeSH-major] Rhabdomyosarcoma / secondary. Soft Tissue Neoplasms / pathology. Testicular Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891513.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Nobili E, Di Cicilia R, Di Battista M, Morselli-Labate AM, Paragona M, Corbelli J, Macchini M, Prandoni P, Biasco G, Brandi G: Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. Pathophysiol Haemost Thromb; 2010;37(1):30-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience.
  • Venous thromboembolism (VTE) may occur during the natural history of neoplastic disease and is a common cause of mortality and morbidity in cancer patients.
  • Chemotherapy is a supplementary independent risk factor for VTE and the use of central venous catheters (CVC) in clinical practice has increased the risk of thromboembolic events.
  • We conducted a retrospective study to evaluate CVC-related thrombosis and the VTE rate in 145 consecutive metastatic colorectal cancer patients.
  • [MeSH-major] Catheterization, Central Venous / adverse effects. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / secondary. Upper Extremity Deep Vein Thrombosis / epidemiology. Venous Thromboembolism / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Morbidity. Outpatients / statistics & numerical data. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Thrombosis.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20956868.001).
  • [ISSN] 1424-8840
  • [Journal-full-title] Pathophysiology of haemostasis and thrombosis
  • [ISO-abbreviation] Pathophysiol. Haemost. Thromb.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Gyergyay F, Gödény M, Sármay G, Kralovanszky J, Papp E, Gergye M, Vincze B, Kéri G, Bodrogi I: Antitumor activity and pharmacology of TT-232 (a novel somatostatin structural derivative) in malignant melanoma patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):3151

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with histologically proven metastatic malignant melanoma had been treated with 480 μg/kg TT-232, daily 4-hour infusion on days 1-7, every second week.
  • The primary tumour localization was the following: trunk:7, head:1, ocular:1, upper extremity:1, lower extremity:2.
  • All pts had previous surgery, 8 had radiotherapy, all received chemotherapy and 11 had immunotherapy as well.
  • One patient had partial remission (lymphnodes) and 3 pts had stable disease (hepatic, mediastinal, rertoperitoneal lymphnodes and pulmonary metastases).Out of 343 days of treatment fever (gr.1-2) has been observed on 8 days.
  • CONCLUSION: TT-232 seems to be a promising new agent in the treatment of malignant melanoma with no obvious toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Veras E, Srodon M, Neijstrom ES, Ronnett BM: Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases. Int J Gynecol Pathol; 2009 Mar;28(2):134-9
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases.
  • Two cases of systemic thromboembolism (Trousseau syndrome) associated with metastatic human papillomavirus (HPV)-related endocervical adenocarcinomas are reported.
  • The first patient, age 36, presented with bilateral lower extremity deep vein thromboses, pulmonary embolism, and supraclavicular and cervical lymphadenopathy.
  • Lymph node biopsy revealed metastatic mucinous adenocarcinoma with focal signet ring cell differentiation.
  • Imaging studies demonstrated metastatic disease without a defined primary site.
  • Acute renal and respiratory failure developed and the patient expired shortly after initiation of chemotherapy, 7 weeks after presentation.
  • Autopsy examination revealed widespread metastatic adenocarcinoma with a 2 cm cervical adenocarcinoma.
  • She developed progressive venous thrombosis despite anticoagulation.
  • Diagnostic laparoscopy with biopsies and left oophorectomy revealed metastatic mucinous adenocarcinoma with signet ring cell differentiation involving peritoneum, ovary, cervix, and bladder without a defined primary site.
  • Progressive thromboembolic disease with acute renal failure and multiple cerebral infarcts developed and the patient expired shortly after initiation of chemotherapy, 2 months after presentation.
  • These features more commonly suggest metastatic adenocarcinoma of upper gastrointestinal tract origin but the presence of HPV DNA within the tumors establishes them as cervical in origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188822.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Aslam SN, Daly RG: Use of recombinant human thyrotropin in a complicated case of metastatic papillary thyroid carcinoma. Endocr Pract; 2001 Mar-Apr;7(2):99-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of recombinant human thyrotropin in a complicated case of metastatic papillary thyroid carcinoma.
  • OBJECTIVE: To describe a complicated case of metastatic papillary thyroid carcinoma and the use of recombinant human thyrotropin (thyroid-stimulating hormone) (rhTSH) in conjunction with treatment with radioactive iodine (131I).
  • RESULTS: A 62-year-old Filipino man with a history of incompletely treated papillary thyroid cancer sought medical assistance in the emergency department because of weakness of the right upper extremity.
  • Further imaging studies disclosed widely metastatic disease.
  • The patient subsequently had a complicated treatment course and received rhTSH in conjunction with 131I treatment.
  • CONCLUSION: This unusual case demonstrates possible complications of metastatic papillary thyroid carcinoma along with innovations in treatment options, including the use of rhTSH to stimulate the uptake of radioiodine by thyroid cancer cells.
  • [MeSH-major] Carcinoma, Papillary / drug therapy. Thyroid Neoplasms / drug therapy. Thyrotropin / therapeutic use
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Humans. Lymph Nodes / pathology. Male. Mediastinal Neoplasms / secondary. Middle Aged. Muscle Weakness / complications. Recombinant Proteins / therapeutic use. Spinal Cord Neoplasms / secondary. Thyroglobulin / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11421553.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


16. Alibhai SM, Gogov S, Allibhai Z: Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol; 2006 Dec;60(3):201-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review.
  • Increasing numbers of men with non-metastatic disease are receiving androgen deprivation therapy (ADT) for a variety of indications, some of which are supported by evidence from randomized trials.
  • Balanced against possible survival benefits and better disease control are data that ADT adversely affects quality of life, particularly in the areas of sexual function, physical function, and energy.
  • There is some evidence of worsening upper extremity physical strength but no clear evidence of decline in daily function with ADT.
  • The impact of ADT on cognitive function is not clear at this time.
  • ADT is associated with declines in bone mineral density within 6-12 months of commencing treatment, with increased fracture rates within 5 years of treatment.
  • It is reasonable for physicians who are about to start men on ADT to obtain a baseline bone mineral density, to counsel them about the impact on sexual function and possible treatments for sexual dysfunction, and to encourage regular exercise.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy


18. Stoll L, Mudali S, Ali SZ: Merkel cell carcinoma metastatic to the thyroid gland: Aspiration findings and differential diagnosis. Diagn Cytopathol; 2010 Oct;38(10):754-7
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma metastatic to the thyroid gland: Aspiration findings and differential diagnosis.
  • Herein, we report a case of metastatic Merkel cell carcinoma to the thyroid presenting as a 2.1-cm solid nodule in a 50-year-old male with a previous history of Merkel cell carcinoma of the upper extremity.
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Biopsy, Fine-Needle. Carcinoma, Small Cell / pathology. Crohn Disease / complications. Crohn Disease / drug therapy. Diagnosis, Differential. Fibrosis / complications. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20082438.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


19. Chow E, Merchant TE, Pappo A, Jenkins JJ, Shah AB, Kun LE: Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):433-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease.
  • PURPOSE: The occurrence of extraosseous Ewing's sarcoma (ES) in deep soft tissues has been well described, but cases in which this tumor occurs in a primary cutaneous or subcutaneous site have rarely been reported.
  • The superficial variant may be less aggressive than are the more common bony and deep soft tissue counterparts with an apparently favorable outcome.
  • Anatomic locations included trunk and pelvis (7), upper or lower extremity (4), and head and neck (3).
  • Thirteen had definitive surgical resections, and one had biopsy of the mass at the time of referral.
  • All patients received chemotherapy, composed of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and dactinomycin.
  • Patients on institutional protocols received radiation (36 Gy) to the operative bed (150-180 cGy/fraction/day).
  • RESULTS: No patients had metastatic disease at presentation.
  • Thirteen patients had wide local excision of the primary tumors prior to enrollment on chemotherapy; surgical margins were negative (10), microscopically positive (2), and indeterminate (1).
  • The patient who had biopsy only received induction chemotherapy followed by definitive surgical resection and postoperative radiotherapy.
  • None of the patients has developed local recurrence or distant metastasis.
  • Several of the patients developed treatment-related sequelae, including veno-occlusive disease of the lung and hemorrhagic cystitis (1), myelodysplastic syndrome (1), chemotherapy-induced ovarian failure (1), moist desquamation (1), and dermatofibroma within the radiotherapy volumes (1).
  • CONCLUSIONS: Cutaneous and subcutaneous ES are associated with an indolent course and a favorable prognosis when treated with combined modality therapy.
  • Elimination of radiation therapy following complete resection has been tested in the POG 9354 trial.
  • The high rate of local control, low rate of metastatic disease, and excellent overall outcome may suggest a role for less intensive chemotherapy, as well as tailoring to diminish or avoid radiation therapy in completely resected cases, with a goal to minimize toxicity while maintaining a high cure rate.
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661351.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S: A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process? Saudi Med J; 2005 Aug;26(8):1190-6
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
  • OBJECTIVE: Within soft-tissue sarcoma, primitive neuroectodermal tumors have been shown to cover a wide spectrum of small round cell sarcomas, including Ewing's sarcomas (ES) and primitive neuroectodermal tumors (PNET).
  • Our aim is to investigate the c-kit expression in ES and PNET and also to assessed if c-kit has any role in disease process.
  • METHODS: We thoroughly searched the archives of the Department of Pathology, Faculty of Medicine, Cukurova University Turkey, between 2000 and 2004; and found 14 ES and 14 PNET paraffin embedded tissues.
  • We carried out the detection of the c-kit expression by immunohistochemical staining.
  • Five were diagnosed as metastatic disease whereas 23 were diagnosed as non-metastatic disease at admission.
  • The main localization of the disease was lower extremity (32.1%), and others were as follows: head and neck 25%, thorax and abdomen 14.3%, pelvic and upper extremity 7.1% (11 were localized skeletal and 17 were extraskeletal).
  • According to treatment modalities, 10 were treated with surgery alone, 11 with surgery and chemotherapy, and 7 with surgery, radiation therapy and also with chemotherapy.
  • There was no significant correlation between c-kit expression and gender, localization, metastatic status, treatment modalities and tumor.
  • CONCLUSION: We suggest that therapy with tyrosine kinase inhibitor for PNET and ES patients may be an alternative in addition to standard therapy modalities, especially in patients non-responsive to standard therapy.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127511.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


21. Moreno Martín-Retortillo L, Andrés Moreno MM, Cañete Nieto A, Castel Sánchez V: Synovial sarcoma in children. A single centre experience. Clin Transl Oncol; 2007 Jul;9(7):468-70
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synovial sarcoma (SS) is a rare disease in the paediatric population, predominating in adolescents.
  • Surgery remains the best treatment strategy for resectable cases.
  • Adjuvant chemotherapy or radiotherapy can be used but have not proven efficacy.
  • Metastatic disease and unsuccessful surgery are major prognostic factors.
  • All of them were affected by SS of upper and lower limbs, and had satisfactory resections with different outcomes in spite of receiving diverse chemotherapy regimens.
  • One of them is at the moment under treatment for relapse, two are disease-free and another died after metastatic disease.
  • [MeSH-major] Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Female. Humans. Lower Extremity. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Upper Extremity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1424-9 [12378447.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(1):37-41 [15170176.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):2006-12 [16161038.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):11-7 [16292743.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3794-803 [11078492.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3697-705 [10577841.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):437-44 [15653701.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):201-9 [9473754.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1602-11 [12697886.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1219 [10561182.001]
  • (PMID = 17652062.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Deshmukh R, Mankin HJ, Singer S: Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res; 2004 Feb;(419):155-61
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective analysis was done on 135 consecutive patients with extremity and truncal synovial sarcomas seen at our institutions between 1961 and 1996.
  • Ninety-nine patients (73%) presented with a newly diagnosed localized primary sarcoma, nine patients (7%) presented with a locally recurrent sarcoma previously treated at another institution, and 27 patients (20%) presented with metastatic disease.
  • Distal location (hands and feet) and histologic grade also were statistically significant predictors of patient survival for localized synovial sarcoma on univariate analysis.
  • Primary tumor size and initial status at presentation were prognostic for survival and patients with synovial sarcomas larger than 5 cm or locally recurrent at presentation should be considered for more aggressive surgical and adjunctive radiotherapy or chemotherapy.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / pathology. Sarcoma, Synovial / mortality. Sarcoma, Synovial / pathology. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged. Neoplasm Staging. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Upper Extremity

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15021147.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ogilvie CM, Crawford EA, Slotcavage RL, King JJ, Lackman RD, Hartner L, Staddon AP: Treatment of adult rhabdomyosarcoma. Am J Clin Oncol; 2010 Apr;33(2):128-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult rhabdomyosarcoma.
  • OBJECTIVES: Rhabdomyosarcoma is an exceedingly rare tumor in adults, and standard chemotherapy used for children is much less effective in adults.
  • Treatment involved surgical resection, radiation therapy, and chemotherapy with doxorubicin, ifosfamide, and vincristine.
  • Tumors sites included upper extremity (4 patients), lower extremity (6), and cervix (1).
  • RESULTS: Of the 7 patients with nonmetastatic disease, 6 had no evidence of disease posttreatment, but 1 died of myelodysplastic syndrome after 51 months.
  • Three patients who received neoadjuvant chemotherapy had 100% tumor necrosis.
  • One patient with positive margins scheduled for adjuvant chemotherapy had local recurrence and metastasis within 2 weeks and died 5 months later.
  • Of the 4 patients with metastatic disease on presentation, 1 had complete response, 2 had partial response with later progression and death at 8 and 24 months, and 1 had immediate progression and died at 12 months.
  • Mean disease-free survival was 17 months for all patients and 23 months for the 7 patients who had remission of all disease.
  • CONCLUSIONS: When combined with surgery and radiation therapy, chemotherapy using doxorubicin, ifosfamide, and vincristine yielded 55% overall and 64% disease-free survival at 2 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770626.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


24. Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Château MC, Marquès B, Picot V, Guillou L: Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol; 2002 May;26(5):601-16
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor locations included lower extremity (36.5%), especially the thigh (28.5%), limb girdles (17.5%), upper extremity (16%), thoracoabdominal wall (9.5%), and internal trunk (20.5%).
  • Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33).
  • Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively.
  • Seventeen patients (35%) died of disease, of whom none was metastatic at diagnosis.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11979090.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


25. Schofer MD, Abu-Safieh MY, Paletta J, Fuchs-Winkelmann S, El-Zayat BF: Liposarcoma of the forearm in a man with type 1 neurofibromatosis: a case report. J Med Case Rep; 2009;3:7071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the forearm in a man with type 1 neurofibromatosis: a case report.
  • We present a case of a dedifferentiated liposarcoma in the forearm, as a complication in a patient with neurofibromatosis type 1.
  • CASE PRESENTATION: A Caucasian man with neurofibromatosis type 1 presented at our clinic complaining of a slow growing swelling on his left forearm over a period of one and a half years.
  • Radiological examination inclusive of magnetic resonance imaging and positron emission tomography confirmed our suspicion.
  • The consulting tumour board recommended either an elbow exarticulation or an accurate radical local resection including the metastatic axillary lymph nodes.
  • The treatment was completed with postoperative radiotherapy of the left forearm's operative bed, the left axillary and the supraclavicular regions.
  • The patient decided against adjuvant chemotherapy.
  • CONCLUSION: Liposarcoma complicating neurofibromatosis type 1 is a very rare combination.
  • It is the first known case with this disease combination in an upper extremity.
  • The role of chemotherapy is controversial and should be based on a decision made on a case-by-case basis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sarcoma. 2008;2008:459386 [18497869.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] J Obstet Gynaecol. 2006 May;26(4):381-2 [16753705.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Cancer. 1963 Aug;16:1015-27 [14050005.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563-72 [9806516.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):540-6 [9344320.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Neurofibromatosis. 1989;2(1):6-22 [2517025.001]
  • [Cites] Bull Hosp Jt Dis Orthop Inst. 1982 Fall;42(2):172-86 [6309294.001]
  • [Cites] Skeletal Radiol. 1981;7(2):150-3 [6800037.001]
  • [Cites] Plast Reconstr Surg. 1978 Feb;61(2):287-90 [414243.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):298-313 [18286473.001]
  • (PMID = 19830134.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2726491
  •  go-up   go-down


26. Maxwell C, Barzilay B, Shah V, Wunder JS, Bell R, Farine D: Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors. Obstet Gynecol; 2004 Aug;104(2):344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors.
  • OBJECTIVE: Primary bone and soft-tissue tumors occur rarely in pregnancy.
  • METHODS: Pregnant women diagnosed with bone or soft-tissue tumors during pregnancy or within 3 months after delivery were identified retrospectively for the years 1983-2003 in the University Health Network database, University of Toronto.
  • Eight cases involved the lower extremity and 6 involved the upper extremity.
  • Osteosarcoma, chondrosarcoma, and giant-cell tumors were the most common histological types.
  • Chemotherapy was deferred until the postpartum period.
  • Three patients were delivered before 37 weeks of gestation to proceed with therapy.
  • One neonate delivered at 34 weeks developed respiratory distress syndrome and required intubation.
  • Three patients died, all as the result of metastatic disease.
  • CONCLUSION: Most cases of soft-tissue and bone tumors during pregnancy can be successfully managed with surgery during gestation.
  • Therapies with fetal toxicity were more likely to be deferred to the postpartum period.
  • [MeSH-major] Bone Neoplasms / epidemiology. Pregnancy Complications, Neoplastic / epidemiology. Soft Tissue Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2005 Feb;105(2):447; author reply 447-8 [15684192.001]
  • (PMID = 15292009.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F: A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer; 2010 Jun 1;116(11):2543-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Axillary reverse mapping (ARM) is a novel technique to preserve upper extremity lymphatics that may reduce the incidence of lymphedema after axillary lymph node dissection.
  • Early reports have suggested that ARM lymph nodes do not contain metastatic disease from breast cancer; however, these studies were conducted in early stage patients with low likelihood of lymph node metastasis.
  • METHODS: Thirty patients, 23 (77%) of whom received preoperative therapy (chemotherapy in 22 patients and hormonal therapy in 1 patient), were enrolled.
  • Blue dye was injected in the upper inner ipsilateral arm.
  • RESULTS: The average time between blue dye injection and axillary exposure was 35 minutes (range, 15-60 minutes).
  • CONCLUSIONS: ARM appears to be a feasible technique with which to identify upper arm lymphatics during axillary surgery.
  • However, the high prevalence of disease involving ARM lymph nodes in this small cohort suggested that preservation of these lymphatics is not oncologically safe in women with documented axillary lymph node metastasis from breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20336790.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS668485; NLM/ PMC4406355
  •  go-up   go-down


28. Asavamongkolkul A, Waikakul S, Phimolsarnti R, Kiatisevi P, Wangsaturaka P: Endoprosthetic reconstruction for malignant bone and soft-tissue tumors. J Med Assoc Thai; 2007 Apr;90(4):706-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
  • BACKGROUND: Nowadays, the results of the management of malignant bone and soft-tissue tumors have been dramatically improved because of the advance in imaging, chemotherapy, radiation therapy, and surgical techniques.
  • Patients can have longer survival times with limb-salvage surgery.
  • OBJECTIVE: To report the preliminary results of 32 endoprosthetic reconstructions following malignant bone and soft-tissue tumor resection.
  • MATERIAL AND METHOD: Since September 1988, the authors have performed 188 limb-salvage surgical operations for the treatment of musculoskeletal tumors at Siriraj Hospital.
  • From March 1994 to July 2006, 32 endoprosthetic reconstructions were performed on 30 patients following malignant bone or soft-tissue tumor removal.
  • The diagnosis was conventional osteosarcoma in 16 patients, parosteal osteosarcoma in two patients, chondrosarcoma in two patients, leiomyosarcoma in two patients, failed allograft in two patients and one patient each of periosteal osteosarcoma, Ewing's sarcoma, Gorham's disease, synovial sarcoma, malignant fibrous histiocytoma, metastatic renal cell carcinoma, and prosthetic loosening.
  • Five proximal femurs, 17 distal femurs, 1 total femur 3 proximal tibias, 1 intercalary tibia, 4 proximal humerus and 1 distal humerus were used for reconstruction.
  • RESULTS: The mean follow-up time was 26 months (range 6-128.7).
  • Sixteen patients are continuously free of the disease, two are alive with the disease, two had no evidence of the disease, nine died of the disease, and one patient died from complication of hypertension.
  • The mean Musculoskeletal Tumor Society functional analysis for upper extremity reconstruction was 93% (range 86.7-100) and for lower extremity was 89% (range 63.3-100).
  • CONCLUSION: Endoprosthetic reconstruction could yield satisfactory results as a wide excision and limb-salvage for patients with malignant bone and soft-tissue tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487125.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down






Advertisement